| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10640 | 2021 |
| The cGAS–STING pathway drives type I IFN immunopathology in COVID-19 JD Domizio, MF Gulen, F Saidoune, VV Thacker, A Yatim, K Sharma, ... Nature 603 (7899), 145-151, 2022 | 343 | 2022 |
| Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) K Sotlar, S Colak, A Bache, S Berezowska, M Krokowski, B Bültmann, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2010 | 172 | 2010 |
| Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry AM Schläfli, S Berezowska, O Adams, R Langer, MP Tschan European journal of histochemistry: EJH 59 (2), 2015 | 158 | 2015 |
| Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis K Sotlar, S Cerny-Reiterer, K Petat-Dutter, H Hessel, S Berezowska, ... Modern Pathology 24 (4), 585-595, 2011 | 150 | 2011 |
| Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis S Berezowska, MJ Flaig, F Ruëff, C Walz, T Haferlach, M Krokowski, ... Modern pathology 27 (1), 19-29, 2014 | 117 | 2014 |
| Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer AM Schläfli, O Adams, JA Galván, M Gugger, S Savic, L Bubendorf, ... Oncotarget 7 (26), 39544, 2016 | 110 | 2016 |
| Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer SQ Liang, TM Marti, P Dorn, L Froment, SRR Hall, S Berezowska, ... Cell death & disease 6 (7), e1824-e1824, 2015 | 89 | 2015 |
| Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer M Niklaus, O Adams, S Berezowska, I Zlobec, F Graber, ... Oncotarget 8 (33), 54604, 2017 | 67 | 2017 |
| miR-29b mediates NF-κB signaling in KRAS-induced non–small cell lung cancers S Langsch, U Baumgartner, S Haemmig, C Schlup, SC Schäfer, ... Cancer research 76 (14), 4160-4169, 2016 | 60 | 2016 |
| A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. C Lu, K Bera, X Wang, P Prasanna, J Xu, A Janowczyk, N Beig, M Yang, ... The Lancet. Digital health 2 (11), e594-e606, 2020 | 50 | 2020 |
| Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas O Adams, B Dislich, S Berezowska, AM Schläfli, CA Seiler, D Kroell, ... Oncotarget 7 (26), 39241, 2016 | 50 | 2016 |
| mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer SQ Liang, ED Bührer, S Berezowska, TM Marti, D Xu, L Froment, H Yang, ... Oncogene 38 (5), 622-636, 2019 | 46 | 2019 |
| Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score–a multicenter study M Diebold, A Soltermann, S Hottinger, SR Haile, L Bubendorf, ... Respiratory research 18, 1-8, 2017 | 46 | 2017 |
| Targeting ErbB receptors in high-grade glioma S Berezowska, J Schlegel Current pharmaceutical design 17 (23), 2468-2487, 2011 | 46 | 2011 |
| Tumor initiation capacity and therapy resistance are differential features of EMT-related subpopulations in the NSCLC cell line A549 CC Tièche, Y Gao, ED Bührer, N Hobi, SA Berezowska, K Wyler, ... Neoplasia 21 (2), 185-196, 2019 | 44 | 2019 |
| High-resolution tissue mass spectrometry imaging reveals a refined functional anatomy of the human adult adrenal gland N Sun, Y Wu, K Nanba, S Sbiera, S Kircher, T Kunzke, M Aichler, ... Endocrinology 159 (3), 1511-1524, 2018 | 44 | 2018 |
| Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas S Berezowska, A Novotny, K Bauer, A Feuchtinger, J Slotta-Huspenina, ... PLoS One 8 (7), e69098, 2013 | 42 | 2013 |
| Combined ATRX/IDH 1 immunohistochemistry predicts genotype of oligoastrocytomas E Hewer, I Vajtai, MS Dettmer, S Berezowska, E Vassella Histopathology 68 (2), 272-278, 2016 | 39 | 2016 |
| Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery E Gallmeier, DC Bader, L Kriegl, S Berezowska, H Seeliger, B Göke, ... PloS one 8 (2), e56760, 2013 | 39 | 2013 |
